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Abstract
Objective
To determine whether alteplase alters the development of ischemic lesions on brain imaging
after stroke.
Methods
The Third International Stroke Trial (IST-3) was a randomized controlled trial of IV alteplase
for ischemic stroke. We assessed CT or brain MRI at baseline (pretreatment) and 24 to
48 hours posttreatment for acute lesion visibility, extent, and swelling, masked to all other data.
We analyzed associations between treatment allocation, change in brain tissue appearances
between baseline and follow-up imaging, and 6-month functional outcome in IST-3. We
performed a meta-analysis of randomized trials of alteplase vs control with pre- and post-
randomization imaging.
Results
Of 3,035 patients recruited in IST-3, 2,916 had baseline and follow-up brain imaging. Pro-
gression in either lesion extent or swelling independently predicted poorer 6-month outcome
(adjusted odds ratio [OR] = 0.92, 95% confidence interval [CI] 0.88–0.96, p < 0.001; OR =
0.73, 95% CI 0.66–0.79, p < 0.001, respectively). Patients allocated alteplase were less likely
than controls to develop increased lesion visibility at follow-up (OR = 0.77, 95% CI 0.67–0.89,
p < 0.001), but there was no evidence that alteplase reduced progression of lesion extent or
swelling. In meta-analysis of 6 trials including IST-3 (n = 4,757), allocation to alteplase was
associated with a reduction in ischemic lesion extent on follow-up imaging (OR = 0.85, 95% CI
0.76–0.95, p = 0.004).
Conclusion
Alteplase was associated with reduced short-term progression in lesion visibility. In meta-
analysis, alteplase reduced lesion extent. These findings may indicate that alteplase improves
functional outcome by reducing tissue damage.
Classification of evidence
This study provides Class II evidence that IV alteplase impedes the progression of ischemic
brain lesions on imaging after stroke.
MORE ONLINE
Class of Evidence
Criteria for rating
therapeutic and diagnostic
studies
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In patients presenting acutely with ischemic stroke, brain im-
aging can demonstrate ischemia and infarction based on water
shifts within brain tissue.1 On CT, brain tissue becomes grad-
ually more hypoattenuated as its water content increases.2
Within the first few hours after stroke onset, there is a reduction
in gray matter attenuation so that gray matter becomes of
similar attenuation to normal white matter resulting in the well-
described loss of visibility of the insular ribbon, basal ganglia, or
affected cortex.3,4 These early attenuation changes of the brain
are often not apparent immediately after symptom onset, but by
24 hours, affected brain is usually obviously hypoattenuated
compared with normal brain,5 and is specific for infarction.6 On
MRI, diffusion-weighted imaging (DWI) can show hyper-
intensity in ischemic tissue within minutes of stroke onset.
Hours later, the lesion also becomes hyperintense on other T2-
weighted sequences7 and, similar to hypoattenuation on CT,
this later change usually indicates infarction.8 Both CT andMRI
show brain tissue swelling as a secondary indicator of injury.
Treatment with IV alteplase within the first few hours after
stroke improves long-term clinical outcome and accelerates
disappearance of arterial obstruction.9–11 However, it is unclear
whether IV alteplase modifies progression of the appearance of
acutely affected brain tissue on imaging (i.e., the ischemic lesion)
over the first 24 to 48 hours after stroke, or whether any short-
term alteplase-related alteration in lesion progression might ex-
plain the long-term improvement in functional outcome.
The Third International Stroke Trial (IST-3) was a large
multicenter, randomized controlled trial testing IV alteplase
given within 6 hours of ischemic stroke.12 In the present
analysis, our aim was to assess the effect of alteplase on any
change in ischemic lesion appearance on CT or MRI between
pretreatment (baseline) and 24- to 48-hour posttreatment
follow-up imaging. We investigated whether alteplase modified
short-term progression of CT hypoattenuation or magnetic
resonance T2-weighted hyperintensity (lesion visibility), lesion
extent, or tissue swelling compared to control and tested
whether alteration in short-term progression of the lesion ap-
pearance predicted long-term functional outcome after ische-
mic stroke. We set our results in the context of a meta-analysis
of all available data from randomized controlled trials.
Methods
Standard protocol approvals, registrations,
and patient consents
IST-3 was an international, multicenter PROBE (pro-
spective, randomized, open-label, blinded endpoint) trial of
IV alteplase (recombinant tissue plasminogen activator)
for ischemic stroke.12 Ethical approval was granted by the
Scotland A research ethics committee and by local ethics
committees. IST-3 was registered with Current Controlled
Trials (ISRCTN25765518). Enrollment, data collection,
and CONSORT (Consolidated Standards of Reporting
Trials) compliance have been described.12,13
Briefly, adult patients with acute stroke of any severity
(assessed with the NIH Stroke Scale [NIHSS]), with no
upper age limit, were eligible if treatment could be started
within 6 hours of symptom onset and brain imaging had
excluded intracranial hemorrhage and structural stroke
mimics. Informed consent for research was obtained for all
patients. The full trial protocol is available: dcn.ed.ac.uk/ist3/.
IST-3 primary results are published.12
Patients were randomly allocated to IV alteplase (0.9 mg/kg)
or control. Treating clinicians used an automated telephone or
online system to enter baseline data and obtain a randomized
treatment allocation. Excepting the first 276 patients (double-
blind phase), treatment was given open label. Patients were
followed up at 6 months by postal or telephone questionnaire
to assess functional status with the Oxford Handicap Scale14 by
assessors whowere masked to clinical and imaging findings and
treatment allocation.
Brain imaging
The IST-3 imaging protocol has been described4,12,15: CT
or MRI was required pretreatment at baseline and follow-
up. For CT, the maximum slice thickness was 5 mm through
the posterior fossa and 10 mm for the cerebrum, but most
CT was performed with thinner slices. MRI included T1,
T2, DWI, fluid-attenuated inversion recovery, and T2*.
DICOM (Digital Imaging and Communications in Medi-
cine) was collated centrally and anonymized. We excluded
patients from the present analysis if images were not re-
ceived centrally.
Image analysis
A panel of 10 experienced neuroradiologists and neurologists
assessed imaging with a secure online viewing tool, which was
developed after extensive review of early ischemic signs3 and
observer reliability testing.4,16,17 The Systematic Image Re-
view System includes a validated data collection pro forma
(available at ed.ac.uk/edinburgh-imaging/image-analysis-
tools), which underwent extensive observer reliability
testing16,17 to ensure there was satisfactory agreement (κ
>0.7) between readers for all imaging features assessed.4
Image assessors were masked to clinical data and treatment
Glossary
ASPECTS = Alberta Stroke Program Early CT Score; CI = confidence interval; DWI = diffusion-weighted imaging; ECASS =
European Cooperative Acute Stroke Study; IQR = interquartile range; IST-3 =Third International Stroke Trial;MCA =middle
cerebral artery; NIHSS = NIH Stroke Scale; OR = odds ratio.
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allocation. We scored baseline imaging (prerandomization)
separately and blindly to follow-up imaging (24–48 hours
after stroke onset) and vice versa, although assessors were
aware if imaging was acquired at baseline or follow-up.
We reviewed all baseline and follow-up imaging for evidence
of acute ischemia/recent infarct (i.e., the acute lesion) using
the validated visual scores to assess 3 features: (1) acute lesion
visibility; (2) location and extent of the lesion; and (3) lesion
swelling.
Acute lesion visibility
We graded acute lesion visibility on a 3-point ordinal scale to
reflect the range of progressive tissue changes seen after is-
chemic stroke, i.e., increasingly more visible CT hypoatten-
uation or MRI T2-weighted hyperintensity (e.g., figure 1).
This schema reflects well-described tissue changes3,4,16,17:
c On CT, we defined acute lesion visibility as grade 0 (no
acute lesion visible); subtle, or grade 1 (gray matter
attenuation equal to that of normal white matter); and
severe, or grade 2 (gray and/or white matter attenuation
lower than normal white matter).
c On MRI, we defined lesions as grade 0 (no lesion);
subtle, or grade 1 (hyperintense area on DWI but not on
other T2-weighted sequences); and severe or grade 2
(hyperintense on T2-weighted sequences with or without
DWI hyperintensity).4
Location and extent of acute lesion
We used the IST-3 Ischemic Lesion Score and ASPECTS
(Alberta Stroke Program Early CT Score) to assess the lo-
cation and extent of acute lesions.18,19
The IST-3 Ischemic Lesion Score records the lesion extent
according to common patterns of infarction in all major vascular
territories (anterior, middle [MCA], and posterior cerebral
arteries), the brainstem, or cerebellum, each with subdivisions. It
includes an 8-point scale for the MCA territory.4,12,18 We con-
densed the detailed scores into fewer groups for analysis, as
described previously4,12: 0 = no acute lesion; 1 = small (e.g.,
lacunar or small cortical lesion); 2 = medium (e.g., striatocap-
sular lesion or superficial MCA territory); 3 = large (e.g., com-
plete MCA territory); and 4 = very large (e.g., complete MCA
plus anterior cerebral artery territories). See data available from
EdinburghDataShare (figure e-1, dx.doi.org/10.7488/ds/2367).
ASPECTS assesses lesion extent only in the MCA territory, in
10 sections, scoring a point for each area that is affected, and
ranges from 10 = normal (no MCA territory lesion) to 0 =
acute lesion affecting the entire MCA territory.19
Acute lesion swelling
We graded tissue swelling on a validated 7-point scale based
on sulcal or ventricular effacement or midline shift, from none
(0) to severe (6 = midline shift with effacement of the basal
cisterns).18 See data available from Edinburgh DataShare
(figure e-2, dx.doi.org/10.7488/ds/2367).
We also assessed baseline scans for leukoaraiosis, atrophy, and
old stroke lesions (i.e., prestroke signs) using validated
scores.4,20–22 We noted the presence of any hemorrhage at
follow-up.
Data analysis
We compared baseline and follow-up imaging to detect
change in any of the acute ischemic lesion appearances. We
subtracted the baseline imaging scores from the follow-up
imaging scores. For the variables lesion visibility grade, IST-3
Ischemic Lesion Score, and swelling, a positive value repre-
sented imaging progression. For ASPECTS, a negative value
represented imaging progression.
We used univariate tests to compare the alteplase and control
groups and to assess for associations with imaging progression.
We then used multivariable ordinal regression to identify pre-
dictors of imaging progression (in those with a significant
univariate association, i.e., change in lesion visibility grade) and
6-month functional outcome. Finally, we tested for interactions
with alteplase between subgroups of variables predictive of
Figure 1 CT andMRI examples of grading of acute ischemic
lesion visibility
(A) CT lesion visibility grade 1; attenuation of affected gray matter (right
lentiform nucleus, arrows) equivalent to normal surrounding white matter.
(B) CT lesion visibility grade 2; attenuation of affected right occipital lobe
(gray andwhitematter, arrows) less than normal whitematter. (C) Diffusion-
weighted and (D) fluid-attenuated inversion recovery (T2-based) imaging
demonstrating MRI lesion visibility grade 1; acute lesion is clearly visible in
panel C (arrows) but only faintly visible in panel D (arrows).
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imaging progression (p < 0.1) on ordinal regression analysis.
Because of the risk of confounding, we did not include
ASPECTS and IST-3 Ischemic Lesion Score in the same
multivariable models. We adjusted regression analyses for the
key outcome predictors of age, NIHSS, time between baseline
and follow-up scans, and presence of hemorrhage at follow-up,
plus leukoaraiosis, atrophy, and old stroke lesions since we
showed previously in IST-3 and other datasets that these pre-
stroke signs affect lesion visibility16,17 and are adverse prog-
nostic markers4,12 (therefore, we did not repeat these tests in
the present analysis). To stabilize regression estimates, we
grouped the variable time between scans into 6 time windows
(0–11, 12–23, 24–35, 36–47, 48–59, 60+ hours) and we
combined the 3 most severe grades of the Oxford Handicap
Scale into a single category, resulting in 5 functional outcome
grades (0, 1, 2, 3, 4–6).
We used IBM SPSS Statistics software, version 21.0 (IBM
Corp., Armonk, NY) for all analyses unless otherwise stated,
and considered p < 0.05 significant.
Meta-analysis
We used the 2014 Cochrane systematic review Thrombolysis
for Acute Ischemic Stroke23 to identify randomized controlled
trials of IV alteplase that reported outcomes by imaging as-
sessment of ischemic lesions at baseline and follow-up. Spe-
cifically, we sought comparable data for the 3 imaging features
examined in IST-3: namely, acute lesion visibility; lesion ex-
tent (scored as lesion volume if assessed at only one time point,
and lesion growth if assessed at more than one time point); and
lesion swelling. In addition, for each relevant trial identified,
we searched PubMed for any post hoc or subgroup analyses
published up to the end of January 2018.
We used Comprehensive Meta-Analysis software, version 2
(Biostat, Englewood, NJ) to compute odds ratios (ORs) of
the alteplase effect for each trial dataset and to calculate
summary statistics using a random effects model. We used I2
statistics to assess heterogeneity between studies.
Data availability
IST-3 data are available on request to bona fide researchers via
Edinburgh DataShare (datashare.is.ed.ac.uk/handle/10283/
1931).
Classification of evidence
Our primary objective was to determine whether alteplase
alters the development of ischemic lesions on brain imaging
after stroke. This study provides Class II evidence that IV
alteplase (0.9 mg/kg) impedes the development of ischemic
brain lesions according to 2 distinct imaging features. In IST-
3, alteplase reduced short-term progression in lesion visibility
(adjusted OR = 0.77, 95% confidence interval [CI]
0.67–0.89), and when combined in meta-analysis with all
available randomized controlled trial data, alteplase reduced
the extent of the ischemic brain lesion on follow-up imaging
(adjusted OR = 0.85, 95% CI 0.76–0.95).
Results
IST-3 recruited 3,035 patients. Baseline or follow-up imaging
was not available for central review in 18 (0.6%) and 105
patients (3.5%), respectively. Central imaging review did not
occur if the patient had died or was too unwell at follow-up, or
if completed scans were never received centrally or were
corrupted. Thus, expert-reviewed baseline and follow-up im-
aging was available for 2,916 patients (96.1%) (data available
from Edinburgh DataShare, figure e-3, dx.doi.org/10.7488/
ds/2367). Most had noncontrast CT performed at baseline
(2,861, 98.1%) and at follow-up (2,766, 94.9%). MRI was
used in 55 and 150 patients, respectively.
For the 2,916 patients included in this analysis, 1,416 (48.6%)
were male, median age was 81 years (interquartile range
[IQR] 72–86 years), and the median baseline NIHSS score
was 11 (IQR 6–17). Median time from stroke onset to
baseline scan was 154 minutes (IQR 105–215 minutes) while
the median time between baseline and follow-up scans was 26
hours (IQR 24–36 hours). Treatment allocation was 1,474
patients (50.5%) to alteplase and 1,442 (49.5%) to control.
We found no differences in demographic or clinical charac-
teristics between the 2,916 patients with complete imaging
data in these analyses and the 3,035 patients in the whole IST-
3 trial (data not shown).
Among the 2,916 patients with complete imaging data, baseline
demographic, clinical, and imaging variables were not different
between treatment groups (table 1), except that patients in the
control group had a slightly longer time lapse between baseline
and follow-up imaging (IQR 24–40 vs 23–30 hours in the
group allocated to alteplase, p < 0.001).
Change in acute lesion between baseline and
follow-up in IST-3
We identified an acute lesion (any of reduced tissue CT
attenuation/increased T2-weighted hyperintensity, or swelling)
in 1,183 patients at baseline and 2,124 patients at follow-up.
Most acute lesions involved the MCA territory (baseline 1,088/
1,178, 92.4%, follow-up 1,722/2,119, 81.3%). We identified any
hemorrhage on 479/2,916 (16.4%) follow-up scans (table 2).
Lesion visibility grade changed between baseline and follow-up
in 1,994/2,916 patients (68.4%). Most patients had no visible
lesion at baseline (1,754/2,916, 60.2%); in contrast, 2,119/
2,916 (72.7%) had a visible lesion at follow-up (table 2). The
prevalence of visible ischemic lesions at baseline did not differ
between patients who presented early (0–3 hours from symp-
tomonset [40.4%]) vs later (4–6 hours [40.8%]) (χ2 = 0.04, p=
0.834). Some lesions completely disappeared (76/2,916, 2.6%)
between baseline and follow-up, fewer became less visible but
remained present (11/2,916, 0.4%). Overall, lesion visibility
increased in fewer patients allocated to alteplase (936/1,474,
63.5%) than to control (971/1,442, 67.3%), and lesion visibility
decreased in more patients allocated to alteplase (46/1,474,
3.1%) than to control (41/1,442, 2.8%) (p = 0.007) (table 3).
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Acute lesion extent increased in 1,344/2,916 (46.1%) on the
IST-3 Ischemic Lesion Score and 1,241/2,916 (42.6%) on
ASPECTS among all patients. Although there were slightly
fewer patients with lesion growth and more with a reduction
in acute lesion extent between baseline and follow-up (on
either IST-3 Ischemic Lesion Score or ASPECTS) among
those allocated to alteplase vs those allocated to control, these
changes were not significant in IST-3 (tables 2 and 3).
Swelling changed (mostly increased) between baseline and
follow-up in 1,494/2,914 patients (51.3%) overall (table 2).
However, there was no difference in the change in swelling
from baseline to follow-up scanning between treatment
groups (table 3).
On ordinal regression analysis, compared with control,
patients allocated to alteplase were less likely to show an
increase in acute lesion visibility grade between baseline and
follow-up scans (OR = 0.77, 95% CI 0.67–0.89, p < 0.001)
(table 4). Leukoaraiosis on baseline imaging independently
predicted a less visible lesion on follow-up imaging (OR =
0.78, 95% CI 0.67–0.91, p = 0.002), but patients with leu-
koaraiosis were less likely to have a visible lesion both at
baseline (562/1,489, 37.7% with leukoaraiosis vs 621/1,427,
43.5% without leukoaraiosis, χ2 = 10.1, p = 0.002) and follow-
up (1,034/1,489, 69.4% with leukoaraiosis vs 1,090/1,427,
76.4% without, χ2 = 17.7, p < 0.001). The following in-
dependently predicted development of a more visible lesion at
follow-up: higher NIHSS score at randomization (OR = 1.06,
95% CI 1.05–1.07, p < 0.001); the presence of an old stroke
lesion at baseline (OR = 1.19, 95% CI 1.03–1.37, p = 0.017);
or hemorrhage on follow-up imaging (OR = 1.62, 95% CI
1.34–1.96, p < 0.001). Our results did not change if patients
with MRI (at either baseline or follow-up) were excluded: in
those with CT at both time points, OR for the effect of
treatment on change in lesion visibility grade = 0.76 (95% CI
0.66–0.88, p < 0.001, n = 2,731; full data not shown).
We found no evidence of an interaction between alteplase and
prespecified subgroups on change in acute lesion visibility grade
between baseline and follow-up (ordinal regression analysis):
baseline stroke severity mild (NIHSS score <8) vs moderate-
severe (NIHSS score ≥8) (p = 0.842); presence vs absence of
leukoaraiosis, atrophy, or old stroke lesions (p = 0.871, p =
0.358, p = 0.239, respectively) (data available from Edinburgh
DataShare, figure e-4, dx.doi.org/10.7488/ds/2367).
Effect of imaging appearances and clinical
features on 6-month outcome in IST-3
On univariate analysis, the change in IST-3 Ischemic Lesion
Score (r = 0.21, p < 0.001), ASPECTS (r = −0.35, p < 0.001),
acute lesion visibility grade (r = 0.22, p < 0.001), and swelling
Table 1 Demographic, clinical, and baseline imaging characteristics of patients allocated to alteplase vs those allocated
to control (n = 2,916)
Characteristic
Treatment allocation
p Value for differenceAlteplase (n = 1,474) Control (n = 1,442)
Age, y 81 (72–86) 81 (71–86) 0.712
Sex, male 720 (48.8) 696 (48.3) 0.754
NIHSS score 11 (6–18) 11 (6–17) 0.953
Time from stroke onset to baseline scan, min 155 (106–214) 151 (105–216) 0.966
Time from baseline to follow-up scan, h 26 (23–30) 26 (24–40) <0.001
OHS grade at 6 mo 3 (2–6) 4 (2–6) 0.152
Baseline imaging appearances
Visible CT hypoattenuation or T2-weighted MRI hyperintensity of brain 603 (40.9) 580 (40.2) 0.706
Brain swelling 348 (23.6) 327 (22.7) 0.551
ASPECTS 10 (8–10) 10 (8–10) 0.388
IST-3 ischemic lesion score 0 (0–2) 0 (0–2) 0.542
Leukoaraiosis 744 (50.5) 745 (51.7) 0.737
Atrophy 1,131 (76.7) 1,114 (77.3) 0.521
Old stroke lesion 676 (45.9) 628 (43.6) 0.210
Abbreviations: ASPECTS = Alberta Stroke Program Early CT Score; IST-3 = Third International Stroke Trial; NIHSS = NIH Stroke Scale; OHS = Oxford Handicap
Scale.
Results are median (interquartile range) or n (%) as appropriate.
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Table 2 Results of central expert panel assessment for the imaging variables assessed at baseline and follow-up (n = 2,916)
Imaging variable Options
Baseline scan
(2,861 CT, 55
MRI)
Follow-up scan
(2,766 CT, 150MRI)
Presence of an acute lesion (either change in tissue CT
attenuation/T2-weighted intensity or swelling)
1,183 (40.6) 2,124 (72.8)
Visibility grade 0 = No attenuation/intensity change 1,754 (60.2) 797 (27.3)
1 = Early tissue changes 974 (33.4) 204 (7.0)
2 = Late tissue changes 188 (6.4) 1,915 (65.7)
Location of acute lesion ACA territory 4/1,178 (0.3) 37/2,119 (1.7)
MCA territory 1,088 (92.4) 1,722 (81.3)
PCA territory 39 (3.3) 108 (5.1)
Vertebrobasilar territory 18 (1.5) 59 (2.8)
Borderzone 7 (0.6) 14 (0.7)
Multiple arterial territories 22 (1.9) 179 (8.4)
ASPECTS 10 1,825 (62.6) 1,118 (38.3)
9 174 (6.0) 232 (8.0)
8 205 (7.0) 230 (7.9)
7 180 (6.2) 265 (9.1)
6 142 (4.9) 198 (6.8)
5 98 (3.4) 176 (6.0)
4 77 (2.6) 116 (4.0)
3 78 (2.7) 132 (4.5)
2 70 (2.4) 112 (3.8)
1 32 (1.1) 134 (4.6)
0 35 (1.2) 203 (7.0)
IST-3 ischemic lesion score 0 = No acute lesion 1,738 (59.6) 797 (27.3)
1 = Small 194 (6.7) 432 (14.8)
2 = Medium 485 (16.6) 723 (24.8)
3 = Large 254 (8.7) 414 (14.2)
4 = Very large 245 (8.4) 550 (18.9)
Degree of tissue swelling None 2,241 (76.9) 1,244/2,914 (42.7)
Effacement of sulci only 534 (18.3) 735 (25.2)
Effacement of sulci and lateral ventricle (minor) 140 (4.8) 658 (22.6)
Effacement of sulci and lateral ventricle
(complete)
0 55 (1.9)
Effacement of sulci, lateral and third ventricles 0 15 (0.5)
Effacement of sulci, lateral and third ventricles
plus midline shift
1 (0.03) 124 (4.3)
Effacement sulci, lateral and third ventricles,
midline shift plus effacement of basal cisterns
0 83 (2.8)
Any hemorrhage on follow-up imaging — 479 (16.4)
Abbreviations: ACA = anterior cerebral artery; ASPECTS = Alberta Stroke Program Early CT Score; IST-3 = Third International Stroke Trial; MCA = middle
cerebral artery; PCA = posterior cerebral artery.
Results are n (%). Data for location of acute lesion and degree of tissue swellingwere not available for all patients at both time points. Presence of hemorrhage
was assessed only at follow-up.
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(r = 0.40, p < 0.001) between baseline and follow-up imaging
were all associated with 6-month functional outcome such
that a worsening of imaging appearances between baseline
and 24–48 hours was associated with worse 6-month func-
tional outcome.
On ordinal regression analysis, the following were in-
dependent predictors of poor outcome: greater age (OR =
0.97, p < 0.001); higher baseline NIHSS score (OR = 0.86, p <
0.001); leukoaraiosis (OR = 0.72, p < 0.001) or atrophy
(OR = 0.77, p = 0.013) on baseline imaging; increasing acute
lesion extent (OR = 0.92, p < 0.001) or swelling (OR = 0.73,
p < 0.001) between baseline and follow-up imaging; and
hemorrhage on follow-up imaging (OR = 0.74, p = 0.017).
Treatment with alteplase (OR = 1.36, p < 0.001) and in-
creased time between baseline and follow-up imaging (OR =
1.10, p = 0.009) independently predicted better outcome at 6
months. Old stroke lesions and increasing visibility grade of
the acute lesion between baseline and follow-up did not in-
dependently predict outcome (table 5). Results were similar if
IST-3 Ischemic Lesion Score was used instead of ASPECTS
to assess change in lesion extent (data not shown).
Table 3 Univariate analyses comparing baseline to follow-up imaging progression between the alteplase vs control
groups
Imaging variable
Imaging change between
scansa
Alteplase
group
Control
group
p Value for difference
between alteplase and control
groupsb
Lesion visibility grade (n = 2,916) Less visible 46 (3.1) 41 (2.8) 0.007
No change 492 (33.4) 430 (29.8)
More visible 936 (63.5) 971 (67.3)
IST-3 ischemic lesion score (n =
2,916)
Smaller lesion 112 (7.6) 101 (7.0) 0.149
No change 695 (47.2) 649 (45.0)
Larger lesion 667 (45.3) 692 (48.0)
ASPECTS (n = 2,916) Smaller lesion 141 (9.6) 134 (9.3) 0.768
No change 639 (43.4) 602 (41.7)
Larger lesion 694 (47.1) 706 (49.0)
Swelling (n = 2,914) Less swelling 35 (2.4) 45 (3.1) 0.402
No change 727 (49.3) 693 (48.1)
More swelling 712 (48.3) 702 (48.8)
Abbreviations: ASPECTS = Alberta Stroke Program Early CT Score; IST-3 = Third International Stroke Trial.
Results represent n (%) within the alteplase and control groups.
a Scalar data have been condensed for simplification in this table.
b The p values are derived from noncondensed data.
Table 4 Ordinal regression analysis of associations between change in lesion visibility grade between baseline and 24- to
48-hour follow-up (dependent variable) and potential clinical and imaging predictors
Change in lesion visibility grade (n = 2,916) Source data Odds ratio 95% CI p Value
Increasing age, y 81 (72–86) 1.01 1.00–1.01 0.100
Increasing baseline NIHSS score 11 (6–17) 1.06 1.05–1.07 <0.001
Leukoaraiosis on baseline imaging 1,489 (51.1) 0.78 0.67–0.91 0.002
Atrophy on baseline imaging 2,245 (77.0) 0.84 0.69–1.02 0.073
Old stroke lesion(s) on baseline imaging 1,304 (44.7) 1.19 1.03–1.37 0.017
Increasing time from baseline to follow-up imaging (12-h groups) 26 (24–36) 1.05 0.99–1.12 0.111
Treatment with alteplase 1,474 (50.5) 0.77 0.67–0.89 <0.001
Any hemorrhage on follow-up imaging 479 (16.4) 1.62 1.34–1.96 <0.001
Abbreviations: CI = confidence interval; NIHSS = NIH Stroke Scale.
Source data summary provided as median (interquartile range) or n (%). Odds ratio >1 indicates a more visible lesion.
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Meta-analysis
There have been no new randomized controlled trials of IV
alteplase vs control since publication of the Cochrane review
in 2014. The Cochrane review already contained a meta-
analysis assessing the alteplase effect on symptomatic edema
in 6 trials (including IST-3), which we did not repeat. Two of
the trial datasets identified using Cochrane (ECASS [Euro-
pean Cooperative Acute Stroke Study], EPITHET [Echo-
planar Imaging Thrombolytic Evaluation Trial])24,25 had
examined lesion growth between baseline and follow-up
similar to IST-3, while 3 of the trials (NINDS [National In-
stitute of Neurological Disorders and Stroke], ATLANTIS
[Alteplase Thrombolysis for Acute Noninterventional Ther-
apy in Ischemic Stroke] A & B)26–28 had measured lesion
volume on follow-up imaging alone (total n = 1,841).
Onmeta-analysis, we found that alteplase impeded lesion growth
(OR = 0.87, 95% CI 0.76–0.99) and was associated with smaller
lesion volumes on follow-up imaging (OR = 0.82, 95% CI
0.67–1.00). When combined in a single meta-analysis including
nearly 5,000 patients from 6 trials (including IST-3), alteplase
reduced progression in the extent of the ischemic lesion (in-
creased lesion growth or greater lesion volume on follow-up
imaging) (OR = 0.85, 95% CI 0.76–0.95, p = 0.004) (figure 2).
Discussion
In this large randomized trial with baseline and follow-up CT
or MRI available for blinded central review in more than 97%
of patients, we found that during the first 24 to 48 hours after
the onset of ischemic stroke, patients allocated to alteplase
were less likely to show progression in the visibility of the
acute lesion compared with controls. Remarkably, less than
50% of patients in both treatment arms showed any lesion
growth. IV alteplase did not reduce significantly the extent of
the acute lesion or alter the degree of lesion swelling in IST-3,
although there were fewer patients with larger lesions and
more patients with smaller or stable lesions at 24 to 48 hours
who received alteplase than control. It seems likely that IST-3
was underpowered to detect this subtle change in lesion ex-
tent, but when IST-3 data were combined in ameta-analysis of
6 randomized controlled trials of alteplase including nearly
5,000 patients, we found that alteplase was associated with
a significant reduction in progression of the ischemic lesion
extent. This alteplase effect includes a reduction in lesion growth
between baseline and follow-up and a smaller lesion volume at
follow-up. We postulate that IV alteplase resulted in fewer
patients either converting an area of reversible ischemia to in-
farction, or expanding their ischemic lesion into tissue that was
unaffected at baseline—both effects result in less injured brain
tissue and may explain the better functional outcome seen fol-
lowing treatment with alteplase.
Background prestroke brain imaging features and baseline
stroke severity were also independent predictors of change in
acute lesion visibility from baseline to follow-up in IST-3.
Patients with old infarcts were more likely to have increased
acute lesion visibility at 24 to 48 hours. Perhaps individuals
with prior infarcts are more likely to develop tissue injury if
they experience another stroke than are patients without old
infarcts on imaging, as suggested for lesion visibility onMRI in
patients with minor stroke.29 Harder to explain is the finding
that prestroke leukoaraiosis appeared to reduce progression of
Table 5 Ordinal regression analysis of 6-month functional outcome (dependent variable) and potential predictors:
Clinical and imaging characteristics (change in the acute lesion from baseline to 24- to 48-hour follow-up;
prestroke features)
OHS grade at 6 mo (n = 2,916) Source data Odds ratio 95% CI p Value
Increasing age, y 81 (72–86) 0.97 0.96–0.98 <0.001
Increasing baseline NIHSS score 11 (6–17) 0.86 0.85–0.87 <0.001
Leukoaraiosis on baseline imaging 1,488 (51.1) 0.72 0.60–0.85 <0.001
Atrophy on baseline imaging 2,243 (77.0) 0.77 0.62–0.95 0.013
Old stroke lesion(s) on baseline imaging 1,304 (44.7) 0.92 0.78–1.07 0.277
Increased lesion visibility grade from baseline to follow-up imaging 1,906 (65.4) 0.97 0.88–1.07 0.525
Worsening ASPECTS (more extensive lesion) from baseline to follow-up imaging 1,399 (48.0) 0.92 0.88–0.96 <0.001
Increased extent of tissue swelling from baseline to follow-up imaging 1,414 (48.5) 0.73 0.66–0.79 <0.001
Increasing time from baseline to follow-up imaging (12-h groups) 26 (24–36) 1.10 1.02–1.18 0.009
Treatment with alteplase 1,474 (50.6) 1.36 1.17–1.58 <0.001
Any hemorrhage on follow-up imaging 479 (16.4) 0.74 0.57–0.95 0.017
Abbreviations: ASPECTS = Alberta Stroke Program Early CT Score; CI = confidence interval; NIHSS = NIH Stroke Scale; OHS = Oxford Handicap Scale.
Source data provided as median (interquartile range) or n (%). Odds ratio >1 indicates an increased likelihood of a better outcome.
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acute lesion visibility at follow-up. This may be because acute
lesions were less often seen in patients with chronically ab-
normal white matter at baseline, a discrepancy that increased
on follow-up imaging, but the reason for this is unclear.
Increased stroke severity (NIHSS) at baseline was a powerful
independent predictor for increased lesion visibility on follow-
up imaging in IST-3 in keeping with current and previously
demonstrated associations between NIHSS, other imaging
measures of severity (hyperattenuated arteries, arterial oc-
clusion on angiography, acute lesion extent), and outcome
after ischemic stroke.10,11,30 However, we found no evidence
of an interaction between alteplase and severe vs mild stroke
or presence/absence of prestroke features on change in acute
lesion visibility; i.e., alteplase worked equally well across all of
these subgroups.
Worsening of imaging appearances from baseline to 24–48
hours independently predicted poor outcome at 6 months in
IST-3. Specifically, greater change in acute lesion extent on
ASPECTS and increased tissue swelling were both associated
with poor outcome. In addition, increased time from baseline
to follow-up imaging was associated with better functional
outcome, perhaps because of residual confounding with
milder strokes being reimaged later. However, despite a sig-
nificant univariate correlation between greater lesion visibility
from baseline to 24- to 48-hour follow-up imaging and
functional outcome, changes in lesion visibility did not in-
dependently predict outcome. This may reflect that increased
lesion visibility in patients at follow-up in our analysis may
include new infarcts appearing since baseline imaging (likely
to affect functional outcome) and early infarcts at baseline
becoming more visible secondary to the expected short-term
tissue changes of infarct (less likely to affect functional out-
come). Whether the transition from ischemic to infarcted
brain can be reliably differentiated using unenhanced CT or
basic MRI sequences remains unproven.
Lack of an association between alteplase and change in the
degree of swelling at 24- to 48-hour follow-up appears to
contrast with the significant excess of symptomatic brain
swelling (that is, severe swelling on follow-up imaging plus
neurologic deterioration within 7 days) among alteplase-
treated patients in the primary IST-3 report.12 However, the
current analysis examined all grades of swelling rather than only
symptomatic swelling, and as noted above, progressive swelling
was associated with worse functional outcome at 6 months.
The limitations of IST-3 have been discussed previously,12
chiefly the potential for bias because of the open trial design;
however, for the present analyses, all readers were masked to
clinical data and treatment allocation. In IST-3, investigators
were required to perform follow-up imaging between 24 and
48 hours unless the patient deteriorated clinically, in which
case immediate rescanning was required; patients who de-
teriorated and hence were scanned sooner were more likely to
have poor 6-month outcomes. Patients treated with alteplase
underwent follow-up imagingmarginally sooner than controls
but had better outcomes overall. It is likely that this marginal
difference in scan interval may reflect the open design and the
Figure 2 Meta-analysis of data from randomized controlled trials of alteplase that assessed short-term lesion growth or
lesion extent on follow-up imaging
For all studies in the combined analysis, I2 = 31.5%. ATLANTIS = Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke; CI =
confidence interval; ECASS = European Cooperative Acute Stroke Study; EPITHET = Echoplanar Imaging Thrombolytic Evaluation Trial; IST-3 = Third In-
ternational Stroke Trial; NINDS = National Institute of Neurological Disorders and Stroke.
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less-pressing need to reimage patients known to have been
allocated to the control group. Although almost all patients
had CT imaging at baseline and follow-up, a few patients were
scanned with different modalities at the 2 time points. It may
not be appropriate to compare acute lesion extent and visi-
bility betweenCT andMRI, though it is perhaps reasonable to
assume that classification of swelling would not differ between
modalities. However, the results remained the same when
those with MRI were excluded from the analysis assessing
change in lesion visibility; we have therefore left all patients in
for completeness. Validated quantitative computational
methods for the assessment of brain imaging are not yet
available for all of the characteristics we assessed in IST-3.
Most important, computational lesion volume measurement
does not distinguish between an increase in volume due to
a true change in lesion extent and an increase in volume due to
more swelling in a lesion of the same extent. We and others
are developing computational lesion assessment methods,31
but their superiority over human visual rating remains un-
proven. Finally, angiographic imaging at baseline and follow-
up was not available. We are aware that we do not know
whether and to what extent treatment with alteplase was as-
sociated with arterial recanalization, and tissue reperfusion.
The strengths of IST-3 include its large sample size, the in-
clusion of patients with a wide range of clinical characteristics
and baseline imaging appearances, and central masked review
of all imaging and visual scoring methods that had undergone
extensive independent validation.16,17
We provide robust evidence that in ischemic stroke, allocation
to alteplase was associated with less progression in the extent
(based on the totality of the randomized evidence from the
meta-analysis) and visibility (in IST-3 alone) of the acute lesion
on short-term imaging follow-up. These findings may reflect
less tissue damage among patients treated with alteplase and
help explain how alteplase improves functional outcome after
ischemic stroke. Alteplase did not alter the development of
lesion swelling, but progression of lesion extent and swelling
were both associated with poorer clinical outcome at 6 months.
Imaging biomarkers of the effect of alteplase on ischemic brain
will be valuable for clinical practice and research. Our findings
indicate that early changes in the ischemic brain lesion are
measurable on imaging, that these imaging appearances can
predict outcome, and that treatment with alteplase limits pro-
gression of the ischemic lesion, which may in turn act as
a surrogate for an improved functional outcome.
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